A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness)

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs SPX 101 (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Acronyms HOPE-1
  • Sponsors Spyryx Biosciences
  • Most Recent Events

    • 24 Jul 2017 Status changed from planning to not yet recruiting.
    • 20 Jun 2017 According to a Spyryx Biosciences media release, this trial will be funded by Cystic Fibrosis Foundation Therapeutics (CFFT).
    • 05 May 2017 This trial is expected to begin in mid-2017, according to a Spyryx Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top